Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L, Ardizzoni E, Atger M, Baudin E, Berikova E, Bonnet M, Chang E, Cloez S, Coit JM, Cox V, de Jong BC, Delifer C, Do JM, Tozzi DDS, Ducher V, Ferlazzo G, Gouillou M, Khan A, Khan U, Lachenal N, LaHood AN, Lecca L, Mazmanian M, McIlleron H, Moschioni M, O'Brien K, Okunbor O, Oyewusi L, Panda S, Patil SB, Phillips PPJ, Pichon L, Rupasinghe P, Rich ML, Saluhuddin N, Seung KJ, Tamirat M, Trippa L, Cellamare M, Velásquez GE, Wasserman S, Zimetbaum PJ, Varaine F, Mitnick CD. Guglielmetti L, et al. Among authors: ferlazzo g. Trials. 2021 Sep 25;22(1):651. doi: 10.1186/s13063-021-05491-3. Trials. 2021. PMID: 34563240 Free PMC article.
Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected Patients in Resource-Constrained Settings.
Huerga H, Mueller Y, Ferlazzo G, Mpala Q, Bevilacqua P, Vasquez B, Noël Mekiedje C, Ouattara A, Mchunu G, Weyenga HO, Varaine F, Bonnet M. Huerga H, et al. Among authors: ferlazzo g. J Acquir Immune Defic Syndr. 2016 Apr 1;71(4):e89-95. doi: 10.1097/QAI.0000000000000895. J Acquir Immune Defic Syndr. 2016. PMID: 26910386
Six-Month Response to Delamanid Treatment in MDR TB Patients.
Hewison C, Ferlazzo G, Avaliani Z, Hayrapetyan A, Jonckheere S, Khaidarkhanova Z, Mohr E, Sinha A, Skrahina A, Vambe D, Vasilyeva I, Lachenal N, Varaine F. Hewison C, et al. Among authors: ferlazzo g. Emerg Infect Dis. 2017 Oct;23(10):1746-8. doi: 10.3201/eid2310.170468. Epub 2017 Oct 17. Emerg Infect Dis. 2017. PMID: 28767036 Free PMC article.
Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P. Ferlazzo G, et al. Lancet Infect Dis. 2018 May;18(5):536-544. doi: 10.1016/S1473-3099(18)30100-2. Epub 2018 Feb 13. Lancet Infect Dis. 2018. PMID: 29452942
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.
Mohr E, Hughes J, Reuter A, Trivino Duran L, Ferlazzo G, Daniels J, De Azevedo V, Kock Y, Steele SJ, Shroufi A, Ade S, Alikhanova N, Benedetti G, Edwards J, Cox H, Furin J, Isaakidis P. Mohr E, et al. Among authors: ferlazzo g. Eur Respir J. 2018 Jun 14;51(6):1800017. doi: 10.1183/13993003.00017-2018. Print 2018 Jun. Eur Respir J. 2018. PMID: 29724920 Free PMC article.
Ambulatory management of pre- and extensively drug resistant tuberculosis patients with imipenem delivered through port-a-cath: A mixed methods study on treatment outcomes and challenges.
Chavan VV, Dalal A, Nagaraja S, Thekkur P, Mansoor H, Meneguim A, Paryani R, Singh P, Kalon S, Das M, Ferlazzo G, Isaakidis P. Chavan VV, et al. Among authors: ferlazzo g. PLoS One. 2020 Jun 16;15(6):e0234651. doi: 10.1371/journal.pone.0234651. eCollection 2020. PLoS One. 2020. PMID: 32544174 Free PMC article.
184 results